Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Feb 15;99(4):651–662. doi: 10.1172/JCI119208

Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

A C Crawley 1, K H Niedzielski 1, E L Isaac 1, R C Davey 1, S Byers 1, J J Hopwood 1
PMCID: PMC507847  PMID: 9045867

Abstract

We report evidence of a dose responsive effect of enzyme replacement therapy in mucopolysaccharidosis type VI cats from birth, at the clinical, biochemical, and histopathological level. Cats treated with weekly, intravenous recombinant human N-acetylgalactosamine-4-sulfatase at 1 and 5 mg/kg, were heavier, more flexible, had greatly reduced or no spinal cord compression, and had almost normal urinary glycosaminoglycan levels. There was near normalization or complete reversal of lysosomal storage in heart valve, aorta, skin, dura, liver, and brain perivascular cells. No reduction in lysosomal vacuolation was observed in cartilage or cornea; however, articular cartilage was thinner and external ear pinnae were larger in some treated cats. Degenerative joint changes were not obviously delayed in treated cats. Skeletal pathology was reduced, with more normalized bone dimensions and with more uniform bone density and trabecular pattern clearly visible on radiographs by 5 to 6 mo; however, differences between 1 and 5 mg/kg dose rates were not clearly distinguishable. At a dose of 0.2 mg/kg, disease was not significantly altered in the majority of parameters examined. Lysosomal storage was present in all tissues examined in the midterm mucopolysaccharidosis type VI fetus and increased rapidly in extent and severity from birth.

Full Text

The Full Text of this article is available as a PDF (908.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguirre G., Raber I., Yanoff M., Haskins M. Reciprocal corneal transplantation fails to correct mucopolysaccharidosis VI corneal storage. Invest Ophthalmol Vis Sci. 1992 Aug;33(9):2702–2713. [PubMed] [Google Scholar]
  2. Alroy J., Freden G. O., Goyal V., Raghavan S. S., Schunk K. L. Morphology of leukocytes from cats affected with alpha-mannosidosis and mucopolysaccharidosis VI (MPS VI). Vet Pathol. 1989 Jul;26(4):294–302. doi: 10.1177/030098588902600402. [DOI] [PubMed] [Google Scholar]
  3. Barton N. W., Brady R. O., Dambrosia J. M., Di Bisceglie A. M., Doppelt S. H., Hill S. C., Mankin H. J., Murray G. J., Parker R. I., Argoff C. E. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991 May 23;324(21):1464–1470. doi: 10.1056/NEJM199105233242104. [DOI] [PubMed] [Google Scholar]
  4. Barton N. W., Furbish F. S., Murray G. J., Garfield M., Brady R. O. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1913–1916. doi: 10.1073/pnas.87.5.1913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Birkenmeier E. H., Barker J. E., Vogler C. A., Kyle J. W., Sly W. S., Gwynn B., Levy B., Pegors C. Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Blood. 1991 Dec 1;78(11):3081–3092. [PubMed] [Google Scholar]
  6. Blumenkrantz N., Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal Biochem. 1973 Aug;54(2):484–489. doi: 10.1016/0003-2697(73)90377-1. [DOI] [PubMed] [Google Scholar]
  7. Breider M. A., Shull R. M., Constantopoulos G. Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I. Am J Pathol. 1989 Mar;134(3):677–692. [PMC free article] [PubMed] [Google Scholar]
  8. Crawley A. C., Brooks D. A., Muller V. J., Petersen B. A., Isaac E. L., Bielicki J., King B. M., Boulter C. D., Moore A. J., Fazzalari N. L. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J Clin Invest. 1996 Apr 15;97(8):1864–1873. doi: 10.1172/JCI118617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Di Ferrante N. M. The measurement of urinary mucopolysaccharides. Anal Biochem. 1967 Oct;21(1):98–106. doi: 10.1016/0003-2697(67)90087-5. [DOI] [PubMed] [Google Scholar]
  10. Evers M., Saftig P., Schmidt P., Hafner A., McLoghlin D. B., Schmahl W., Hess B., von Figura K., Peters C. Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8214–8219. doi: 10.1073/pnas.93.16.8214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gold E. W. A simple spectrophotometric method for estimating glycosaminoglycan concentrations. Anal Biochem. 1979 Oct 15;99(1):183–188. doi: 10.1016/0003-2697(79)90061-7. [DOI] [PubMed] [Google Scholar]
  12. Haskins M. E., Aguirre G. D., Jezyk P. F., Patterson D. F. The pathology of the feline model of mucopolysaccharidosis VI. Am J Pathol. 1980 Dec;101(3):657–674. [PMC free article] [PubMed] [Google Scholar]
  13. Haskins M. E., Bingel S. A., Northington J. W., Newton C. D., Sande R. D., Jezyk P. F., Patterson D. F. Spinal cord compression and hindlimb paresis in cats with mucopolysaccharidosis VI. J Am Vet Med Assoc. 1983 May 1;182(9):983–985. [PubMed] [Google Scholar]
  14. Haskins M. E., Jezyk P. F., Patterson D. F. Mucopolysaccharide storage disease in three families of cats with arylsulfatase B deficiency: leukocyte studies and carrier identification. Pediatr Res. 1979 Nov;13(11):1203–1210. doi: 10.1203/00006450-197911000-00001. [DOI] [PubMed] [Google Scholar]
  15. Hollak C. E., Aerts J. M., Goudsmit R., Phoa S. S., Ek M., van Weely S., von dem Borne A. E., van Oers M. H. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet. 1995 Jun 10;345(8963):1474–1478. doi: 10.1016/s0140-6736(95)91037-9. [DOI] [PubMed] [Google Scholar]
  16. Hoogerbrugge P. M., Brouwer O. F., Bordigoni P., Ringden O., Kapaun P., Ortega J. J., O'Meara A., Cornu G., Souillet G., Frappaz D. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet. 1995 Jun 3;345(8962):1398–1402. doi: 10.1016/s0140-6736(95)92597-x. [DOI] [PubMed] [Google Scholar]
  17. Hopwood J. J., Harrison J. R. High-resolution electrophoresis of urinary glycosaminoglycans: an improved screening test for the mucopolysaccharidoses. Anal Biochem. 1982 Jan 1;119(1):120–127. doi: 10.1016/0003-2697(82)90674-1. [DOI] [PubMed] [Google Scholar]
  18. Hopwood J. J., Vellodi A., Scott H. S., Morris C. P., Litjens T., Clements P. R., Brooks D. A., Cooper A., Wraith J. E. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis type I patients with a defined genotype. J Inherit Metab Dis. 1993;16(6):1024–1033. doi: 10.1007/BF00711520. [DOI] [PubMed] [Google Scholar]
  19. Jezyk P. F., Haskins M. E., Patterson D. F., Mellman W. J., Greenstein M. Mucopolysaccharidosis in a cat with arylsulfatase B deficiency: a model of Maroteaux-Lamy syndrome. Science. 1977 Nov 25;198(4319):834–836. doi: 10.1126/science.144321. [DOI] [PubMed] [Google Scholar]
  20. Krivit W., Pierpont M. E., Ayaz K., Tsai M., Ramsay N. K., Kersey J. H., Weisdorf S., Sibley R., Snover D., McGovern M. M. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med. 1984 Dec 20;311(25):1606–1611. doi: 10.1056/NEJM198412203112504. [DOI] [PubMed] [Google Scholar]
  21. McGovern M. M., Ludman M. D., Short M. P., Steinfeld L., Kattan M., Raab E. L., Krivit W., Desnick R. J. Bone marrow transplantation in Maroteaux-Lamy syndrome (MPS type 6): status 40 months after BMT. Birth Defects Orig Artic Ser. 1986;22(1):41–53. [PubMed] [Google Scholar]
  22. Menon K. P., Tieu P. T., Neufeld E. F. Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I. Genomics. 1992 Nov;14(3):763–768. doi: 10.1016/s0888-7543(05)80182-x. [DOI] [PubMed] [Google Scholar]
  23. Norrdin R. W., Moffat K. S., Thrall M. A., Gasper P. W. Characterization of osteopenia in feline mucopolysaccharidosis VI and evaluation of bone marrow transplantation therapy. Bone. 1993 May-Jun;14(3):361–367. doi: 10.1016/8756-3282(93)90165-7. [DOI] [PubMed] [Google Scholar]
  24. Richards S. M., Olson T. A., McPherson J. M. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood. 1993 Sep 1;82(5):1402–1409. [PubMed] [Google Scholar]
  25. Sands M. S., Vogler C., Kyle J. W., Grubb J. H., Levy B., Galvin N., Sly W. S., Birkenmeier E. H. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest. 1994 Jun;93(6):2324–2331. doi: 10.1172/JCI117237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Shull R. M., Kakkis E. D., McEntee M. F., Kania S. A., Jonas A. J., Neufeld E. F. Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12937–12941. doi: 10.1073/pnas.91.26.12937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Shull R. M., Lu X., McEntee M. F., Bright R. M., Pepper K. A., Kohn D. B. Myoblast gene therapy in canine mucopolysaccharidosis. I: Abrogation by an immune response to alpha-L-iduronidase. Hum Gene Ther. 1996 Aug 20;7(13):1595–1603. doi: 10.1089/hum.1996.7.13-1595. [DOI] [PubMed] [Google Scholar]
  28. Turner A. S., Norrdin R. W., Gaarde S., Connally H. E., Thrall M. A. Bone mineral density in feline mucopolysaccharidosis VI measured using dual-energy X-ray absorptiometry. Calcif Tissue Int. 1995 Sep;57(3):191–195. doi: 10.1007/BF00310257. [DOI] [PubMed] [Google Scholar]
  29. Varadi D. P., Cifonelli J. A., Dorfman A. The acid mucopolysaccharides in normal urine. Biochim Biophys Acta. 1967 Jun 13;141(1):103–117. doi: 10.1016/0304-4165(67)90249-8. [DOI] [PubMed] [Google Scholar]
  30. Vogler C., Sands M. S., Levy B., Galvin N., Birkenmeier E. H., Sly W. S. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival. Pediatr Res. 1996 Jun;39(6):1050–1054. doi: 10.1203/00006450-199606000-00019. [DOI] [PubMed] [Google Scholar]
  31. Vogler C., Sands M., Higgins A., Levy B., Grubb J., Birkenmeier E. H., Sly W. S. Enzyme replacement with recombinant beta-glucuronidase in the newborn mucopolysaccharidosis type VII mouse. Pediatr Res. 1993 Dec;34(6):837–840. doi: 10.1203/00006450-199312000-00028. [DOI] [PubMed] [Google Scholar]
  32. Wenger D. A., Gasper P. W., Thrall M. A., Dial S. M., LeCouteur R. A., Hoover E. A. Bone marrow transplantation in the feline model of arylsulfatase B deficiency. Birth Defects Orig Artic Ser. 1986;22(1):177–186. [PubMed] [Google Scholar]
  33. Yogalingam G., Litjens T., Bielicki J., Crawley A. C., Muller V., Anson D. S., Hopwood J. J. Feline mucopolysaccharidosis type VI. Characterization of recombinant N-acetylgalactosamine 4-sulfatase and identification of a mutation causing the disease. J Biol Chem. 1996 Nov 1;271(44):27259–27265. doi: 10.1074/jbc.271.44.27259. [DOI] [PubMed] [Google Scholar]
  34. Yoshida M., Ikadai H., Maekawa A., Takahashi M., Nagase S. Pathological characteristics of mucopolysaccharidosis VI in the rat. J Comp Pathol. 1993 Aug;109(2):141–153. doi: 10.1016/s0021-9975(08)80258-7. [DOI] [PubMed] [Google Scholar]
  35. Yoshida M., Noguchi J., Ikadai H., Takahashi M., Nagase S. Arylsulfatase B-deficient mucopolysaccharidosis in rats. J Clin Invest. 1993 Mar;91(3):1099–1104. doi: 10.1172/JCI116268. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES